Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial - American Journal of Transplantation
Blockage of interleukin-1β with canakinumab in patients with Covid-19 | Scientific Reports
Assessment of Tocilizumab (Anti–Interleukin‐6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody‐Mediated Rejection and Transplant Glomerulopathy in HLA‐Sensitized Renal Allograft Recipients - Choi - 2017 - American Journal of ...
Vaccines | Free Full-Text | Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
Pharmaceutics | Free Full-Text | Effects of Tocilizumab on Inflammation and Iron Metabolism in Critically Ill Patients with COVID-19
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes - ScienceDirect
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes - ScienceDirect
Antibiotics | Free Full-Text | Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study
Interleukin 6 Inhibition and Coronary Artery Disease in a High‐Risk Population: A Prospective Community‐Based Clinical Study | Journal of the American Heart Association
RoActemra, INN-tocilizumab
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) | Annals of the Rheumatic Diseases
COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine - American Journal of Transplantation
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial - The Lancet
RoActemra, INN-tocilizumab
Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Strategies to Manage Tocilizumab Supply During the COVID-19 Pandemic - Ontario COVID-19 Science Advisory Table
Anti-hIL-6R mAbs | Tocilizumab | InvivoGen
Tocilizumab in patients with severe COVID-19: a retrospective cohort study - The Lancet Rheumatology
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes - ScienceDirect
Tocilizumab in patients with severe COVID-19: a retrospective cohort study - The Lancet Rheumatology
RoActemra, INN-tocilizumab
THU0088 PREDICTORS OF DISEASE FLARE AFTER DISCONTINUATION OF CONCOMITANT METHOTREXATE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH TOCILIZUMAB | Annals of the Rheumatic Diseases
Tocilizumab in COVID-19 management: addressing time of starting treatment | European Journal of Hospital Pharmacy
Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA) - eClinicalMedicine
Hyaluronate–Gold Nanoparticle/Tocilizumab Complex for the Treatment of Rheumatoid Arthritis | ACS Nano
